Accueil / Communiqués / Sensei Biotherapeutics To Present First Preclinical Data on SNS-723 and Long-Term Clinical Results on SNS-301 Data at The 2019 American Association for Cancer Research (AACR) Annual Meeting

Sensei Biotherapeutics To Present First Preclinical Data on SNS-723 and Long-Term Clinical Results on SNS-301 Data at The 2019 American Association for Cancer Research (AACR) Annual Meeting

Thursday, February 28th 2019 at 1:01pm UTC

GAITHERSBURG, Md.–(BUSINESS WIRE)– Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company
developing precision immuno-oncology therapies, today announced that it
will present novel preclinical data on SNS-723, a first-in-class CAR-T
cell therapy and additional Phase 1 data on the long-term effects of
SNS-301, a first-in-class cancer immunotherapy, both targeting a novel
tumor specific embryonic antigen, human aspartate ?-hydroxylase (ASPH),
at the American Association for Cancer Research (AACR) Annual Meeting in
Atlanta, Georgia March 29 – April 3, 2019.

Poster Session Details:

Poster Title: CAR-T cell therapies targeting aspartyl ?-hydroxylase
(ASPH)
Session Date and Time: Monday, April 1: 1:00-5:00pm ET
Session
Title: Adoptive Cell Therapy 2
Location: Exhibit Hall B, Poster
Section 22, Poster Board 5
Abstract Number: 2306

Poster Title: Long-term immunogenicity results from a first-in-human
study evaluating the anti-ASPH cancer vaccine, SNS-301
Session Date
and Time: Monday April 1: 8:00am – 12:00pm ET
Session Title: Cancer
Vaccines and Intratumoral Immunomodulation
Location: Exhibit Hall
B, Poster Section 22, Poster Board 9
Abstract Number: 1454

About SNS-723

SNS-723 is a first-in-class CAR-T cell therapy that is currently in
preclinical development targeting human aspartate ?-hydroxylase (ASPH),
a cell surface enzyme that is normally expressed during fetal
development. The recognition domain of the CAR is the scFv portion of a
high affinity anti-ASPH mAb. SNS-723 is designed to overcome one of the
major hurdles in T-cell therapy, the identification of antigens that
permit effective targeting of tumors in the absence of non-tolerable
and/or off-target toxicities to essential tissues and organs.
Experiments to further characterize ASPH-targeted CAR-T cells are
ongoing with the goal of moving these promising therapeutics into clinic.

About SNS-301

SNS-301 is a first-in-class cancer immunotherapy targeting human
aspartate ?-hydroxylase (ASPH), a cell surface enzyme that is normally
expressed during fetal development. Following fetal development, the
protein is no longer expressed. Expression of ASPH is uniquely
upregulated in more than 20 different cancer types and promotes cancer
cell growth, cell motility and invasiveness. ASPH expression levels in
various tumors are inversely correlated with tumor resistance and
patient survival. Through enhanced antigen presentation and other
engineered immunotherapeutic features, SNS-301 is designed to overcome
self- tolerance and induce robust and durable ASPH-specific humoral and
cellular immune responses. SNS-301 is paired with a companion diagnostic
to select antigen-positive patients and is delivered intradermally for
ease of administration.

About Sensei Biotherapeutics

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company
developing precision immuno-oncology therapies to transform the cancer
treatment landscape. The company is using its proprietary drug discovery
platform, called SPIRIT, to discover and develop both vaccines and
T-cell therapies, including SNS-301, its clinical stage cancer vaccine,
and SNS-723, its cell therapy program in preclinical development for
solid tumors and hematological cancers. These programs target ASPH, a
novel embryonic antigen. Sensei’s precision medicine approach in
immuno-oncology includes the use of companion diagnostics to select
patients who are most likely to respond to its tumor-specific antigen
therapies. Sensei Biotherapeutics is located in Gaithersburg, MD. For
more information, please visit www.senseibio.com.

Contacts

Media:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investors:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie@sternir.com

Source: Sensei Biotherapeutics, Inc.


Voir aussi

Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update

Thursday, March 21st 2019 at 4:45pm UTC Executed strategic agreement for Imeglimin with Roivant Sciences; …